JP2013536825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536825A5 JP2013536825A5 JP2013526452A JP2013526452A JP2013536825A5 JP 2013536825 A5 JP2013536825 A5 JP 2013536825A5 JP 2013526452 A JP2013526452 A JP 2013526452A JP 2013526452 A JP2013526452 A JP 2013526452A JP 2013536825 A5 JP2013536825 A5 JP 2013536825A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- pharmaceutical composition
- composition according
- represent
- times greater
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 23
- 229910052805 deuterium Inorganic materials 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 229960003638 dopamine Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- YGRHOYQMBLLGEV-DWPKPNNESA-N 1-(1,1,2,2,3,3,3-heptadeuteriopropyl)-4-(3-methylsulfonylphenyl)piperidine;hydrochloride Chemical compound Cl.C1CN(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-DWPKPNNESA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- PVWOIHVRPOBWPI-NCKGIQLSSA-N 1,1,1,2,2,3,3-heptadeuterio-3-iodopropane Chemical compound [2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])I PVWOIHVRPOBWPI-NCKGIQLSSA-N 0.000 description 1
- YGKUEOZJFIXDGI-MADFRBAASA-N 1-(1,1,2,2,3,3,3-heptadeuteriopropyl)-4-(3-methylsulfonylphenyl)piperidine Chemical compound C1CN(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-MADFRBAASA-N 0.000 description 1
- BFFDEVPWGSZYSN-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)piperidine Chemical compound CS(=O)(=O)C1=CC=CC(C2CCNCC2)=C1 BFFDEVPWGSZYSN-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 0 CC(*)(C(*)(*)*)C(*)(*)N(C(*)(*)C(*)(*)*1c2c(*)c(S(C(*)(*)*)(=O)=O)c(*)c(C)c2*)C(*)(*)C1(*)*=C Chemical compound CC(*)(C(*)(*)*)C(*)(*)N(C(*)(*)C(*)(*)*1c2c(*)c(S(C(*)(*)*)(=O)=O)c(*)c(C)c2*)C(*)(*)C1(*)*=C 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070385 | 2010-09-03 | ||
| DKPA201070385 | 2010-09-03 | ||
| US38085110P | 2010-09-08 | 2010-09-08 | |
| US61/380,851 | 2010-09-08 | ||
| PCT/EP2011/064954 WO2012028635A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536825A JP2013536825A (ja) | 2013-09-26 |
| JP2013536825A5 true JP2013536825A5 (https=) | 2014-10-23 |
Family
ID=44653278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526452A Pending JP2013536825A (ja) | 2010-09-03 | 2011-08-31 | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20130197031A1 (https=) |
| EP (1) | EP2611759A1 (https=) |
| JP (1) | JP2013536825A (https=) |
| KR (1) | KR20140008297A (https=) |
| CN (1) | CN103249697B (https=) |
| AU (2) | AU2011298382A1 (https=) |
| BR (1) | BR112013005125A2 (https=) |
| CA (1) | CA2810092A1 (https=) |
| CL (1) | CL2013000604A1 (https=) |
| EA (1) | EA201390332A1 (https=) |
| IL (1) | IL224776A (https=) |
| MX (1) | MX2013002453A (https=) |
| NZ (1) | NZ608120A (https=) |
| PE (1) | PE20140105A1 (https=) |
| PH (1) | PH12013500406A1 (https=) |
| SG (2) | SG188298A1 (https=) |
| WO (1) | WO2012028635A1 (https=) |
| ZA (1) | ZA201301902B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SI2146961T1 (sl) * | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| SG188298A1 (en) * | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| HRP20221106T1 (hr) | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| US10459055B2 (en) * | 2017-04-07 | 2019-10-29 | Case Western Reserve University | System and method for reduced field of view MR fingerprinting for parametric mapping |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| MX2022010006A (es) | 2020-02-13 | 2022-09-19 | Prilenia Neurotherapeutics Ltd | Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. |
| CN115551505B (zh) | 2020-05-04 | 2026-03-17 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| US20230181362A1 (en) | 2020-05-20 | 2023-06-15 | Nthalmic Holding Pty Ltd | Methods and apparatus to manage meibomian gland deficiencies |
| MX2022014599A (es) * | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2026080658A1 (en) | 2024-10-10 | 2026-04-16 | Prilenia Therapeutics Inc. | Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
| JP2008501749A (ja) | 2004-06-08 | 2008-01-24 | ニューロサーチ スウェーデン アクチボラゲット | ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| CA2629514A1 (en) | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US8288414B2 (en) * | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017015515A1 (en) | 2015-07-23 | 2017-01-26 | Knowles Electronics, Llc | Microphone with temperature sensor |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| CN109906270A (zh) | 2016-09-16 | 2019-06-18 | 嘉吉公司 | 经遗传修饰的乳酸消耗酵母以及使用此类经遗传修饰的酵母的发酵工艺 |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| NL2019473B1 (en) | 2017-09-01 | 2019-03-11 | Isobionics B V | Terpene Synthase producing patchoulol and elemol, and preferably also pogostol |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2011
- 2011-08-31 SG SG2013014022A patent/SG188298A1/en unknown
- 2011-08-31 AU AU2011298382A patent/AU2011298382A1/en not_active Abandoned
- 2011-08-31 CA CA 2810092 patent/CA2810092A1/en not_active Abandoned
- 2011-08-31 EA EA201390332A patent/EA201390332A1/ru unknown
- 2011-08-31 US US13/820,024 patent/US20130197031A1/en not_active Abandoned
- 2011-08-31 BR BR112013005125A patent/BR112013005125A2/pt not_active IP Right Cessation
- 2011-08-31 KR KR20137007971A patent/KR20140008297A/ko not_active Ceased
- 2011-08-31 SG SG10201506761XA patent/SG10201506761XA/en unknown
- 2011-08-31 CN CN201180042460.5A patent/CN103249697B/zh active Active
- 2011-08-31 WO PCT/EP2011/064954 patent/WO2012028635A1/en not_active Ceased
- 2011-08-31 EP EP20110757801 patent/EP2611759A1/en not_active Withdrawn
- 2011-08-31 MX MX2013002453A patent/MX2013002453A/es active IP Right Grant
- 2011-08-31 PE PE2013000359A patent/PE20140105A1/es not_active Application Discontinuation
- 2011-08-31 PH PH1/2013/500406A patent/PH12013500406A1/en unknown
- 2011-08-31 JP JP2013526452A patent/JP2013536825A/ja active Pending
- 2011-08-31 NZ NZ60812011A patent/NZ608120A/en not_active IP Right Cessation
-
2013
- 2013-02-18 IL IL224776A patent/IL224776A/en not_active IP Right Cessation
- 2013-03-01 CL CL2013000604A patent/CL2013000604A1/es unknown
- 2013-03-13 ZA ZA2013/01902A patent/ZA201301902B/en unknown
-
2015
- 2015-12-14 US US14/968,522 patent/US20160166559A1/en not_active Abandoned
- 2015-12-14 US US14/968,510 patent/US20160095847A1/en not_active Abandoned
-
2016
- 2016-10-26 AU AU2016250390A patent/AU2016250390A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,041 patent/US20180235950A1/en not_active Abandoned
- 2018-09-17 US US16/133,192 patent/US10799492B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536825A5 (https=) | ||
| CN103249697B (zh) | 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物 | |
| EP2408446B1 (en) | Use of pharmaceutical compositions containing mesembrenone | |
| WO2009044392A3 (en) | Novel sirna structures | |
| DK3029039T3 (en) | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE | |
| JP2014515351A5 (https=) | ||
| JP2020519654A5 (https=) | ||
| JP2013506670A5 (https=) | ||
| JP2010515682A5 (https=) | ||
| JP2006500403A (ja) | キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用 | |
| JP2016540749A5 (https=) | ||
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| CN101646650B (zh) | 亚型选择性氮杂二环烷烃衍生物 | |
| MX2007007722A (es) | Sales de amonio cuaternario como antagonistas de m3. | |
| US20100179118A1 (en) | Cyclic aminoalkylcarboxamide derivative | |
| JP2011500819A5 (https=) | ||
| US20220213099A1 (en) | Prodrug compounds | |
| JP6634157B2 (ja) | ジアミノピリジン誘導体 | |
| NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
| PH12016500197A1 (en) | Novel biphenyl derivative and method for preparing same | |
| TW200406414A (en) | Substituted amino isoxazoline derivatives and their use as anti-depressants | |
| EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| CN103121970A (zh) | 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用 | |
| TH98482B (th) | เกลือซินาโฟเอตของสารประกอบ5-ออกซาโซล-2-อิล-ควิโนลีนที่ถูกแทนที่ |